Cardiac resynchronization therapy: Prospect for long-lasting heart failure remission

Shinning Sun, Jose A. Joglar

Research output: Contribution to journalArticle

Abstract

Heart failure (HF) remains an important heath care problem in the United States. With the aging of the US population, this trend is expected to continue. However, patients have also benefited from advances in pharmacologic and device-based therapies such as angiotensin-converting enzyme inhibitors, β-blockers, aldosterone blockers, and implantable cardioverter- defibrillators. More recently, cardiac resynchronization therapy (CRT) has become another important therapeutic option for treating heart failure due to systolic dysfunction. In this article, we review the physiologic basis for CRT, the clinical trials that support its efficacy, and the current indications for its use. We also examine key clinical questions regarding CRT still under research, including predictors of response. Finally, we look at the future of CRT and how its indications can be expanded to benefit more patients in the future.

Original languageEnglish (US)
Pages (from-to)887-892
Number of pages6
JournalJournal of Investigative Medicine
Volume59
Issue number6
DOIs
StatePublished - Aug 2011

Fingerprint

Cardiac resynchronization therapy
Cardiac Resynchronization Therapy
Heart Failure
Implantable cardioverter defibrillators
Implantable Defibrillators
Aldosterone
Angiotensin-Converting Enzyme Inhibitors
Aging of materials
Clinical Trials
Equipment and Supplies
Therapeutics
Research
Population

Keywords

  • Biventricular pacemaker
  • Cardiac resynchronization therapy
  • Congestive heart failure
  • ICD
  • Intraventricular conduction delay
  • Mechanical dyssynchrony

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cardiac resynchronization therapy : Prospect for long-lasting heart failure remission. / Sun, Shinning; Joglar, Jose A.

In: Journal of Investigative Medicine, Vol. 59, No. 6, 08.2011, p. 887-892.

Research output: Contribution to journalArticle

@article{9e8d80a679b243fea1aedd5c3708629b,
title = "Cardiac resynchronization therapy: Prospect for long-lasting heart failure remission",
abstract = "Heart failure (HF) remains an important heath care problem in the United States. With the aging of the US population, this trend is expected to continue. However, patients have also benefited from advances in pharmacologic and device-based therapies such as angiotensin-converting enzyme inhibitors, β-blockers, aldosterone blockers, and implantable cardioverter- defibrillators. More recently, cardiac resynchronization therapy (CRT) has become another important therapeutic option for treating heart failure due to systolic dysfunction. In this article, we review the physiologic basis for CRT, the clinical trials that support its efficacy, and the current indications for its use. We also examine key clinical questions regarding CRT still under research, including predictors of response. Finally, we look at the future of CRT and how its indications can be expanded to benefit more patients in the future.",
keywords = "Biventricular pacemaker, Cardiac resynchronization therapy, Congestive heart failure, ICD, Intraventricular conduction delay, Mechanical dyssynchrony",
author = "Shinning Sun and Joglar, {Jose A.}",
year = "2011",
month = "8",
doi = "10.231/JIM.0b013e3182186320",
language = "English (US)",
volume = "59",
pages = "887--892",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cardiac resynchronization therapy

T2 - Prospect for long-lasting heart failure remission

AU - Sun, Shinning

AU - Joglar, Jose A.

PY - 2011/8

Y1 - 2011/8

N2 - Heart failure (HF) remains an important heath care problem in the United States. With the aging of the US population, this trend is expected to continue. However, patients have also benefited from advances in pharmacologic and device-based therapies such as angiotensin-converting enzyme inhibitors, β-blockers, aldosterone blockers, and implantable cardioverter- defibrillators. More recently, cardiac resynchronization therapy (CRT) has become another important therapeutic option for treating heart failure due to systolic dysfunction. In this article, we review the physiologic basis for CRT, the clinical trials that support its efficacy, and the current indications for its use. We also examine key clinical questions regarding CRT still under research, including predictors of response. Finally, we look at the future of CRT and how its indications can be expanded to benefit more patients in the future.

AB - Heart failure (HF) remains an important heath care problem in the United States. With the aging of the US population, this trend is expected to continue. However, patients have also benefited from advances in pharmacologic and device-based therapies such as angiotensin-converting enzyme inhibitors, β-blockers, aldosterone blockers, and implantable cardioverter- defibrillators. More recently, cardiac resynchronization therapy (CRT) has become another important therapeutic option for treating heart failure due to systolic dysfunction. In this article, we review the physiologic basis for CRT, the clinical trials that support its efficacy, and the current indications for its use. We also examine key clinical questions regarding CRT still under research, including predictors of response. Finally, we look at the future of CRT and how its indications can be expanded to benefit more patients in the future.

KW - Biventricular pacemaker

KW - Cardiac resynchronization therapy

KW - Congestive heart failure

KW - ICD

KW - Intraventricular conduction delay

KW - Mechanical dyssynchrony

UR - http://www.scopus.com/inward/record.url?scp=84856454109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856454109&partnerID=8YFLogxK

U2 - 10.231/JIM.0b013e3182186320

DO - 10.231/JIM.0b013e3182186320

M3 - Article

C2 - 21441824

AN - SCOPUS:84856454109

VL - 59

SP - 887

EP - 892

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 6

ER -